Implant-delivered Alendronate Causes a Dose-dependent Response on Net Bone Formation Around Porous Titanium Implants in Canines.

BACKGROUND: Bony fixation of cementless orthopaedic implants is not always achieved, particularly in challenging scenarios such as revision surgery, trauma, and tumor reconstruction. An adjunct therapy for improving porous implant fixation could improve the reliability and durability of these reconstructive procedures. QUESTIONS/PURPOSES: In this study, we asked whether there is a positive and dose-dependent effect of the local release of the bisphosphonate alendronate from (1) alendronate/hydroxyapatite (HA) porous-coated titanium implants compared with bare metal porous controls; and (2) alendronate/HA on porous-coated titanium implants compared with HA-coated porous controls with respect to extent of bone ingrowth, bone apposition, and periimplant bone formation in a canine model? METHODS: Three-dimensional printed porous-coated cylindrical implants coated with three different doses (0.02, 0.06, and 0.18 mg/cm(2)) of alendronate were inserted bilaterally in the intramedullary canal of the proximal femora of 15 adult mongrel dogs (age range, 3-9 years; mean, 5 years) weighing between 36 kg and 60 kg (mean, 43 kg). In each dog, an implant coated with HA and one of three different doses of alendronate was inserted on one side while the contralateral femur had a bare metal porous control implant and an identical control implant with a coating of HA. The dose effect of locally released alendronate on the extent of bone ingrowth, bone apposition, and periimplant bone was assessed by backscattered electron microscopy of three pairs of cross-sections taken from each implant at 12 weeks after surgery. A linear mixed model was used to perform the statistical analyses to account for the correlation in the data resulting from the multiple measures performed on each dog. RESULTS: Compared with paired bare metal controls, periimplant bone increased by 92% (p = 0.007), and 114% (p < 0.001) in the femora with the alendronate implants with a dose of 0.06 mg/cm(2), or 0.18 mg/cm(2), respectively. At a dose of 0.02 mg/cm(2), there was no difference (46% change; p = 0.184, with the numbers available). The comparison of the alendronate-dosed implants with their HA-coated controls showed that the intermediate dose of 0.06 mg/cm(2) alendronate had the greatest effect on net bone formation. Bone apposition was enhanced with the 0.06-mg/cm(2) alendronate femoral implants (82%; p = 0.008), although there was no change in bone ingrowth (37% change; p = 0.902, with the numbers available). When compared with the HA-coated control implants, the greatest effect of the alendronate-dosed implants was the increased amount of periimplant bone at the intermediate dose of 0.06-mg/cm(2) (108%, p = 0.009). There was no effect of the low (0.02-mg/cm(2)) and high (0.18-mg/cm(2)) alendronate-dosed implants (4%, and 6%, respectively; p = 0.321, p = 0.502). Overall, all three alendronate-dosed implants revealed little to no effect on bone ingrowth compared with the HA-coated control implants. CONCLUSIONS: The local release of alendronate from a three-dimensional printed porous-coated implant from the three doses studied showed an overall improvement in bone apposition and periimplant bone at the intermediate dose compared with bare metal or with HA-coated controls, although the effect was more pronounced compared with bare metal. Long-term studies to show the effects of localized alendronate delivery and mechanical fixation would be the next step for future studies. CLINICAL RELEVANCE: Local release of alendronate from a three-dimensional printed porous-coated implant may improve the reliability of cementless fixation of currently available porous-coated bare metal implants.

Local alendronic acid elution increases net periimplant bone formation: a micro-CT analysis.

BACKGROUND: Fixation of cementless orthopaedic implants is not always achieved, particularly in challenging scenarios such as revision surgery, trauma, and tumor reconstruction. An adjunct therapy for improving implant fixation would improve the reliability and durability of certain reconstructive procedures. QUESTIONS/PURPOSES: The purpose of this study was to determine the effect of local elution of the bisphosphonate alendronic acid on bone formation around porous titanium implants in an animal model. METHODS: Porous-coated cylindrical rods were coated with either 0.2 mg or 1.0 mg alendronic acid before bilateral surgical implantation into the femoral intramedullary canals of 10 experimental dogs. Twelve weeks after surgery, the femora were harvested and scanned with micro-CT to quantify the percentage volume of bone within the immediate periimplant space. Four femora from two dogs were also processed for undecalcified thin-section histology and analysis with backscattered scanning electron microscopy. Three histologic sections from each of these four femora were anatomically matched with transverse micro-CT sections to enable direct comparison of the area fraction of bone within the periimplant space. RESULTS: Compared with paired controls, micro-CT analysis showed that local elution of alendronic acid increased periimplant bone at both doses of 0.2 mg (+52%, p = 0.01) and 1.0 mg (+152%, p = 0.004) with 1.0 mg resulting in a 2.9-fold greater mean relative increase compared with 0.2 mg (p = 0.002). Micro-CT measurements of periimplant bone formation correlated very strongly with the backscattered scanning electron microscopy measurements (R = 0.965, p < 0.001). CONCLUSIONS: Local elution of alendronic acid causes a dose-dependent net increase in periimplant bone formation in an animal model. CLINICAL RELEVANCE: This concept has potential to improve the biologic fixation of porous reconstructive implants.

The Otto Aufranc Award: Demineralized bone matrix around porous implants promotes rapid gap healing and bone ingrowth.

BACKGROUND: Noncemented revision arthroplasty is often complicated by the presence of bone implant gaps that reduce initial stability and biologic fixation. Demineralized bone matrix has osteoinductive properties and therefore the potential to enhance gap healing and porous implant fixation. QUESTIONS/PURPOSES: We determined at what times and to what extent demineralized bone matrix promotes gap healing and bone ingrowth around a porous implant. METHODS: We inserted porous titanium implants into the proximal metaphyses of canine femora and humeri, with an initial 3-mm gap between host cancellous bone and implants. We left the gaps empty (control; n = 12) or filled them with either demineralized bone matrix (n = 6) or devitalized demineralized bone matrix (negative control; n = 6) and left them in situ for 4 or 12 weeks. We quantified volume healing of the gap with new bone using three-dimensional micro-CT scanning and quantified apposition and ingrowth using backscattered scanning electron microscopy. RESULTS: The density of bone inside gaps filled with demineralized bone matrix reached 64% and 93% of surrounding bone density by 4 and 12 weeks, respectively. Compared with empty controls and negative controls at 4 and 12 weeks, gap healing using demineralized bone matrix was two to three times greater and bone ingrowth and apposition were up to 15 times greater. CONCLUSIONS: Demineralized bone matrix promotes rapid bone ingrowth and gap healing around porous implants. CLINICAL RELEVANCE: Demineralized bone matrix has potential for enhancing implant fixation in revision arthroplasty.

Size, shape, and composition of wear particles from metal-metal hip simulator testing: effects of alloy and number of loading cycles.

There has been a revived interest in metal-metal total hip replacements because of their potential for improved wear performance compared with conventional metal-polyethylene implants. The aim of the present study was to characterize metal wear particles isolated from metal-metal hip simulator testing of various clinically relevant alloys and to analyze the effects of these alloys and the number of loading cycles on wear particle characteristics. Implants were manufactured using medical-grade cobalt-chromium-molybdenum (CoCrMo) alloys that were high-carbon wrought, low-carbon wrought, or cast (with solution annealing). Testing was performed in a MATCO orbital bearing hip simulator in 95% bovine calf serum. The wear particles were isolated from the serum at test periods of 0-0.25 million cycles (Mc) (run-in wear) and 1.75-2 Mc (steady-state wear) using an enzymatic protocol previously optimized to minimize particle changes due to reagents. Isolated particles embedded in epoxy resin were characterized by transmission electron microscopy (TEM) and energy dispersive X-ray analysis (EDXA). The EDXA results revealed the predominance of "lighter" particles containing Cr and O (most likely chromium oxide particles from the passivation layer) and fewer darker CoCrMo particles, with varying ratios of Co and Cr (possibly from carbides and from implant matrix material). More CoCrMo particles were observed with the low-carbon wrought alloy, but the majority of the particles for all three alloys was chromium oxides, especially for the 1.75-2 Mc test period. Image analysis of TEM micrographs revealed that for 0-0.25 Mc, there was up to 21% needle-shaped particles but that the majority remained round to oval in shape, reflecting the predominance of chromium oxide particles. Particle length averaged about 52 +/- 4 nm, with only small differences due to the alloy. For 1.75-2 Mc, most particles were round to oval in shape. They were even less needle-shaped than at 0.25 Mc, and they had a slightly smaller length, averaging 46 +/- 3 nm. In addition to characterizing the size and shape of particles from a MATCO simulator, this study is the first to demonstrate that particles that do not contain Co (presumably chromium oxides) can be predominant in the wear of metal-metal hip implants. It is therefore recommended that future in vitro and in vivo studies include the effects of these particles rather than just the effects of CoCrMo particles on the overall tissue response.

Extracortical bone bridging in tumor endoprostheses. Radiographic and histologic analysis.

BACKGROUND: Aseptic loosening remains a major problem following prosthetic replacement after resection of periarticular tumors. Attempts to decrease the rate of loosening led to the introduction of a composite segmental prosthesis in which the shoulder of the intramedullary stem is porous-coated to allow extracortical bone bridging and bone ingrowth. The purposes of this study were to determine the extent of extracortical bone bridging around, and the amount of bone growth into, the porous-coated shoulder of endoprostheses implanted following the resection of periarticular bone tumors and to correlate the radiographic and histologic findings. METHODS: Twenty tumor endoprostheses implanted with use of the extracortical bone-bridging technique were evaluated radiographically to determine the extent of extracortical bone and the amount of bone ingrowth. Five of these endoprostheses were retrieved and subjected to histologic analysis with backscattered electron microscopy and transmitted light microscopy to determine the extent of bone ingrowth. RESULTS: At a mean of twenty-eight months postoperatively, varying amounts of extracortical bone formation were seen radiographically in all patients. Radiographs also appeared to show bone growth into the porous-coated segment of all implants. However, histologic analysis of the five retrieved prostheses revealed that none of the extracortical bone had actually grown into the porous-coated segment of the implant. CONCLUSIONS: This study confirmed that autogenous bone-grafting of the bone-implant junction of a tumor endoprosthesis consistently results in the formation of extracortical bone. Although radiographs seemed to indicate that this bone grows into the porous coating, this was not confirmed histologically. Growth of extracortical bone into the extramedullary, porous-coated portion of tumor endoprostheses in humans may not be attainable with the current prosthetic design and surgical technique.

Comparison of in vitro with in vivo characteristics of wear particles from metal-metal hip implants.

The purpose of the present study was to compare wear particles isolated from metal-metal (MM) hip implants worn in an orbital bearing simulator with particles from similar MM total hip replacement (THR) implants worn in vivo. Comparison of these particles is important because it will help to assess the overall suitability of this type of hip simulator for reproducing in vivo wear and for producing physiological wear particles suitable for biological studies of in vitro cellular response. Commercial grade components made of ASTM F75 (cast) alloy were evaluated. Simulator tests were performed in 95% bovine calf serum with a 28-mm-diameter implant. Wear particles were collected from 0 to 0.25 million cycles (run-in wear period) and 1.75 to 2 million cycles (steady-state wear period). Tissues from seven patients with MM implants (surface replacement or stem type) were harvested at revision surgeries (after 1-43 months). Metal wear particles were isolated from serum lubricant or tissues using an enzymatic protocol that was previously optimized to minimize particle changes due to reagents. After isolation, particles were centrifuged, embedded in epoxy resin, and characterized by transmission electron microscopy (TEM) and energy dispersive X-ray analysis (EDXA). Results of EDXA on particles from the hip simulator primarily indicated a predominance of particles containing Cr and O but no Co (most likely chromium oxide particles), and fewer CoCrMo particles presenting varying ratios of Co and Cr. Image analysis of TEM micrographs demonstrated that the majority of the particles from the simulator were round to oval, but a substantial number of needle-shaped particles were also found, especially from 0 to 0.25 Mc. The particles generated from 0 to 0.25 Mc had an average length of 53 nm, whereas those generated from 1.75 to 2 Mc had an average length of 43 nm. In vivo, EDXA and TEM analysis of particles that were retrieved from two patients at 23 and 43 months respectively, revealed that they were the most comparable in composition, average length (57 nm), and shape to particles generated in the hip simulator during the run-in wear period. Because a large clinical retrieval study in the literature suggested that a run-in wear regime might occur in vivo for some 6-36 months, the fidelity of the simulator of the present study was strongly supported. However, some uncertainties existed, including the finding that the particles isolated from the other five patients generated from 1 month up to 15 months (shorter implantation times than the other two patients) were smaller and mostly contained only Cr and O (no Co). In the opinion of the authors, this particular very short term patient group was somewhat atypical. Therefore, despite these uncertainties, the present study was deemed to support the ability of the orbital bearing hip simulator to produce physiological wear particles.

The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution.

The bisphosphonate zoledronic acid chemically and physically was bound to hydroxyapatite-coated porous tantalum implants. The zoledronic acid elution characteristics in saline were determined as a function of time and the in vivo effects of elution were quantified at 12 weeks in a canine ulnar implant model. Intramedullary implants surgically were implanted bilaterally into the ulnae of a control group of five dogs and a zoledronic acid-dosed (0.05 mg zoledronic acid) group of four dogs. Computerized image analysis of undecalcified histologic sections was used to quantify the amount of peri-implant bone within the intramedullary canal, the percentage of available pore space filled with new bone, and the number and size of the individual bone islands within the implant pores. The data were analyzed using a hierarchical analysis of variance with 95% confidence intervals. The peri-implant bone occupied a mean of 13.8% of the canal space in controls and 32.2% of the canal space in zoledronic acid-dosed dogs, a relative difference of 134% (2.34-fold) that was significant. The mean extent of bone ingrowth was 12.5% for the control implants and 19.8% for the zoledronic acid-dosed dogs, a relative difference of 58% that was statistically significant. Individual islands of new bone formation with the implant pores were similar in number in both implant groups but were 71% larger on average in the ZA-dosed group. We are the first authors to show that local elution of a bisphosphonate can cause substantial bone augmentation around and within porous orthopaedic implants. The concept represents a potential tool for restoration of bone stock and enhancement of implant fixation in primary and revision cementless joint arthroplasty surgeries in the face of compromised or deficient bone.